The group's principal activity is to develop novel therapeutic products for the treatment of cancer and chronic viral infections. The company's most advanced clinical programs include drug candidates for the treatment of ovarian cancer, chronic Hepatitis B & C and solid tumors. The lead product from the AIT™ platform is OvaRex® MAb, a therapy for late-stage ovarian cancer. OvaRex® MAb is currently the subject of a pivotal Phase III clinical trial at more than 60 sites in the United States.
Executive Information
Name
Title
Email
Darrell Elliott
Chmn., Interim CEO
N/A
Bruce Hirsche
Corp. Sec.
N/A
Lorne Tyrrell
Dir., CEO, Chief Scientific Officer
N/A
Macaraig Canton
COO, Pres.
N/A
Richard Ascione
Member - Scientific Advisory Board, Interim Chief Scientific Officer
